S7Y
alosetron
Created: | 2020-03-05 |
Last modified: | 2021-03-13 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 40 |
Chiral Atom Count | 0 |
Bond Count | 43 |
Aromatic Bond Count | 15 |
Chemical Component Summary | |
---|---|
Name | alosetron |
Synonyms | 5-methyl-2-[(4-methyl-1~{H}-imidazol-5-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one |
Systematic Name (OpenEye OEToolkits) | 5-methyl-2-[(4-methyl-1~{H}-imidazol-5-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one |
Formula | C17 H18 N4 O |
Molecular Weight | 294.351 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | CACTVS | 3.385 | Cn1c2CCN(Cc3[nH]cnc3C)C(=O)c2c4ccccc14 |
SMILES | OpenEye OEToolkits | 2.0.7 | Cc1c([nH]cn1)CN2CCc3c(c4ccccc4n3C)C2=O |
Canonical SMILES | CACTVS | 3.385 | Cn1c2CCN(Cc3[nH]cnc3C)C(=O)c2c4ccccc14 |
Canonical SMILES | OpenEye OEToolkits | 2.0.7 | Cc1c([nH]cn1)CN2CCc3c(c4ccccc4n3C)C2=O |
InChI | InChI | 1.03 | InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19) |
InChIKey | InChI | 1.03 | JSWZEAMFRNKZNL-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank ID | DB00969 |
---|---|
Name | Alosetron |
Groups |
|
Description | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured bowel, and death. In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. |
Synonyms |
|
Brand Names |
|
Indication | Only for the treatment of symptoms of severe diarrhea-predominant irritable bowel syndrome (IBS) in women with chronic symptoms (generally lasting greater than 6 months) who does not present with anatomic or biochemical GI abnormalities and have not responded to conventional therapy. |
Categories |
|
ATC-Code | A03AE01 |
CAS number | 122852-42-0 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
5-hydroxytryptamine receptor 3A | MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVR... | unknown | antagonist |
Cytochrome P450 1A2 | MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL... | unknown | substrate,inhibitor |
Cytochrome P450 3A4 | MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI... | unknown | substrate |
Cytochrome P450 2C9 | MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI... | unknown | substrate |
Cytochrome P450 2E1 | MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLEL... | unknown | inhibitor |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL1110 |
PubChem | 2099 |
ChEMBL | CHEMBL1110 |
ChEBI | CHEBI:253342 |